Phase II study of FOLFIRI plus Bevacitumab in the treatment of Japanese patients with advanced colorectal cancer.
Phase 2
- Conditions
- Colorectal cancer
- Registration Number
- JPRN-UMIN000001437
- Lead Sponsor
- Japan Clinical Cancer Research Organization
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
(1) Contraindications of using CPT-11, Bevacitumab, 5-FU and Leucovorin (2) Having double or more cancers within 5 yeras. (3).Pregnancy or lactation women, or women with suspected pregnancy or men with willing to get pregnant. (4) Any subject judged by the investigator to be unfit for any reason to participate in the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression free survival
- Secondary Outcome Measures
Name Time Method Time to tretment failure Overall survival Response rete Safety